Literature DB >> 507990

Cardiovascular and autonomic actions of ciclazindol and tricyclic antidepressants.

J F Waterfall, M A Smith, W H Gaston, J Maher, G Warburton.   

Abstract

The novel antidepressant ciclazindol had no significant effect on blood pressure at doses of up to 25.6 mg/kg i.v. in anaesthetised rats. Desipramine, imipramine, nortriptyline and amitriptyline evoked significant decreases at 0.8-1.6 mg/kg. Ciclazindol had no sustained haemodynamic actions in anaesthetised cats apart from a small rise in dp/dt. The ECG waveform showed only minor voltage changes. Desipramine and nortriptyline elevated haemodynamic variables at low doses but decreases occurred at higher doses. Amitripyline and imipramine decreased blood pressure. ECG changes evoked by the tricyclics included QRS complex distortion, ventricular ectopic beats, nodal rhythm, bundle branch block and ventricular tachycardia. In skin wheal tests ciclazindol was equiactive with the tricyclics as a local anaesthetic. In isolated tissues ciclazindol was not anticholinergic, showed no marked antagonism of 5-HT, potentiated responses to noradrenaline and was weakly antihistaminic. Ciclazindol appears to be pharmacologically different from the tricyclics and may not produce the unwanted side effects associated with these compounds.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 507990

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  3 in total

1.  Comparison of the effects of chronic administration of ciclazindol and desipramine on pupillary responses to tyramine, methoxamine and pilocarpine in healthy volunteers.

Authors:  F A Kerr; E Szabadi
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

2.  Tricyclic antidepressant amitriptyline alters sarcoplasmic reticulum calcium handling in ventricular myocytes.

Authors:  Aleksey V Zima; Jia Qin; Michael Fill; Lothar A Blatter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-09-12       Impact factor: 4.733

3.  Ciclazindol: an oral agent with weight reducing properties and hypoglycaemic activity.

Authors:  M E Lean; L J Borthwick
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.